Industry landscapes
The companies, capital and talent shaping life sciences in the United Kingdom. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
163 of 3,337 tracked companies have open roles.
1,126 of 3,337 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 2,292 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 15.0% of disclosed capital, while 66.3% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $1.34B | 168 | 151 |
| 2017 | $1.72B | 193 | 177 |
| 2018 | $2.56B | 187 | 192 |
| 2019 | $2.19B | 206 | 201 |
| 2020 | $3.01B | 212 | 217 |
| 2021 | $5.51B | 143 | 240 |
| 2022 | $2.53B | 110 | 196 |
| 2023 | $2.23B | 82 | 182 |
| 2024 | $3.63B | 50 | 186 |
| 2025 | $3.04B | 24 | 130 |
Share of all disclosed company funding.
2,651 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Thrive Capital and Alphabet and others.
Backed by Venrock.
Backed by 4Bio Capital and Servier and others.
Backed by PXN Ventures and IQ Capital and others.
Backed by Jon Moulton and The GM&C Life Sciences Fund.
Backed by Eos Advisory and Oshen and others.
Backed by Innovateuk.
Backed by NLC.
Backed by Thrive Capital and Alphabet and others.
Backed by Ally Bridge Group and Railpen and others.
Backed by Thrive Capital and Google Ventures and others.
Backed by Forbion and General Atlantic and others.
Backed by Boehringer Ingelheim.
Backed by Lilly and Woodford Investment Management and others.
Backed by Escala Capital and Watrium and others.
Backed by M&G and Temasek and others.
Backed by Novo Holdings and BlackRock and others.
Backed by Patient Square Capital and M&G and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 12 reporting entities from 1048 eligible matches.
Sum of reporting-entity revenue; not the United Kingdom market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
6 of 12 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 12 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| LabLogic Systems ↗02062398 | £14.8m | £3.1m | +20.7% | — | — |
| Constructive Bio ↗13758641 | £10.8m | £-0.5m | -4.9% | — | — |
| Oxford Gene Technology ↗03845432 | £10.3m | £-0.4m | -3.4% | — | — |
| Nourished ↗12009187 | £10.2m | £-0.7m | -6.7% | — | — |
| PharmaFootpath ↗14504862 | £0.1m | £0.0m | +3.5% | — | — |
| De Soutter Medical ↗03164365 | £0.1m | £17.4m | +21186.7% | — | — |
| IntelliHep ↗04437155 | £0.0m | £-0.0m | -21.2% | — | — |
| Algotec Research and Development ↗11877462 | £0.0m | £0.0m | 0.0% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the the United Kingdom companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
18 of the 3,337 companies on this page carry a measured traffic record (0.5%); these are the largest of those, by monthly visits. The median among them is 218,477 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Overleafoverleaf.com | 41,836,176 | 74 | 9.2% |
| Nutrition Geeksnutritiongeeks.co | 3,014,560 | 44 | 95.6% |
| Ankhwayankhway.com | 825,348 | 21 | 95.7% |
| Heightsheights.com | 593,889 | 38 | 92.7% |
| Wild Nutritionwildnutrition.com | 460,213 | 40 | 92% |
| BetterVitsbettervits.co.uk | 455,686 | 27 | 96.8% |
| Cytivacytivalifesciences.com | 386,483 | 45 | 54.9% |
| Do Not Agedonotage.org | 301,119 | 31 | 64.7% |
| Alyvealyvewellness.com | 226,380 | 25 | 96.1% |
| Second Naturesecondnature.io | 210,575 | 47 | 82.6% |
Visits and authority are third-party web estimates, not company-reported figures.
88 of these companies (2.6%) publish at least one Android app — 127 apps in all, carrying 1.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Pump with ElvieElvie | 239K | 4 | Health & Fitness |
| Second NatureSecond Nature | 225.9K | 3.9 | Health & Fitness |
| Caura: For #AllThingsCarCaura | 178.1K | — | Auto & Vehicles |
| Elvie TrainerElvie | 120K | 4.1 | Health & Fitness |
| MiniMed WeCareMedtronic Diabetes | 74.9K | — | Health & Fitness |
| AnSo Anaesthesia SonoanatomyAnSo | 69.3K | 2.6 | Medical |
| Revitive: Leg TherapyRevitive | 58.7K | 3.8 | Medical |
| ExSeed: Sperm & Fertility AppExseed Health | 54.2K | — | Health & Fitness |
| Brain in HandBrain in Hand | 29.3K | — | Health & Fitness |
| sofisofi | 25.9K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 30 | 743.5K | Pump with Elvie 239K | |
| Wearable Technology | 25 | 626.6K | Caura: For #AllThingsCar 178.1K | |
| Women Health | 9 | 363.1K | Elvie Trainer 120K | |
| Online Mom & Baby Care | 6 | 362.7K | Neebo 2K | |
| Consumer Electronics E-Commerce | 4 | 359.6K | Elvie Strong | Kegel Exercises 644 | |
| Nutraceuticals Tech | 6 | 263.3K | Second Nature 225.9K | |
| Diabetes | 4 | 253.2K | MiniMed WeCare 74.9K | |
| Fitness & Wellness Tech | 17 | 249.4K | Habitual 6.3K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 102 of 127 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
130 companies hiring · $33.38B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease, has raised $5 million.
Advanced Medical Solutions said on Monday that it is in negotiations with U.S. private equity firm TA Associates over a potential takeover of the British medical supplier.
STORM Therapeutics, a Cambridge-based clinical-stage biotech company focused on RNA-targeted cancer therapies, has raised $56 million in Series C funding.
Creo Medical Group has entered into an agreement to sell its manufacturing operations to Creo’s current manufacturing operations management as a management buyout for an undisclosed amount.
Herbalife acquired the personalized nutrition company Bioniq
H.I.G. Capital-backed Vernacare has acquired Cardiff-based Eakin Surgical from Eakin Healthcare Group.
Advanced skincare and cosmetics company Corryn Biotechnologies has secured a £500,000 equity investment to support commercialisation and scale-up of its cosmetic aftercare products in the UK and US.
Digital Science’s acquisition of Ontopic aims to enhance research intelligence and knowledge discovery through advanced data integration and extraction technologies.
Roquefort has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Avacta Group plc (...) has completed an oversubscribed equity raise of £10 million gross proceeds through a placing of 15,000,000 new ordinary shares and a director subscription for a further 873,016 shares
Top 10 categories among 1,570 recorded events in the 24-month window.
25 companies with recorded IPO activity
Follow-on Offering · Nasdaq2 reports
Follow-on Offering · Nasdaq Capital Market2 reports
OFS · NASDAQ4 reports
IPO · Nasdaq1 reports
IPO1 reports
Follow-on Offering · AIM1 reports
Follow-on Offering · Nasdaq1 reports
IPO · London Stock Exchange4 reports
93 tracked people moves
Retirement Previously chief compliance officer
Appointment Division President
Appointment Chief Executive Officer
Appointment Chief Executive Officer
Appointment Director
Appointment Director
Appointment executive managing director, institutional consulting
Departure Previously CFO and director
48 recorded customer wins
Customer: boehringer ingelheimBiopharmaceutical
Customer: Life Sciences
Customer: leading European medical research centre
Customer: seawith
Customer: US biopharmaceutical companylife sciences
Customer: superdrug storesRetail
11 companies with reported reductions
224 rolesregulatory setback
14 rolesbusiness wind-up
25.0% rolescost reduction
76 rolescost reduction
17 rolescost reduction
40 rolesstrategic review
29 recorded events
voucher grantedFDA
approved for storage and distribution
approved for Phase 3 trialEMA
8 tracked suits
Investor damages due to alleged misstatements of clinical trial outcomesClass Action · Ongoing
Misleading statements about Phase 3 studies leading to inflated share priceSecurities Fraud · Filed
Reported company results in the recorded window.
Median across 162 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| ta associates→Advanced Medical Solutions ↗ | Rumored | 2026-04-21 | Not stated in snapshot |
| newco→Creo Medical ↗ | Announced | 2026-04-16 | Not stated in snapshot |
| herbalife→Bioniq ↗ | Completed | 2026-04-14 | Not stated in snapshot |
| metagenics→Symprove ↗ | Completed | 2026-04-14 | Not stated in snapshot |
| vernacare→eakin surgical | Announced | 2026-04-09 | Not stated in snapshot |
| Digital Science→ontopic | Announced | 2026-03-30 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
55 postings in the preceding 12 months. The full 293-posting snapshot covers 17 employers.
10 tracked postings mention remote work.
8 postings specify a level.
Top skills across 293 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| Oxford Instruments ↗ | 2,027 |
| Bespak ↗ | 2,000 |
| ConvaTec Group ↗ | 971 |
| Epredia ↗ | 863 |
| Advanced Medical Solutions ↗ | 719 |
| Nanopore Technologies ↗ | 705 |
| Judges Scientific ↗ | 622 |
| Allergy Therapeutics ↗ | 601 |
2,359 founders and chief executives across 1,659 companies.
University of Cambridge BA, UCL PhD
Ex-Radiometer · Ghent University MSc 1999
University of the Witwatersrand MB, University of Cape Town, University of Cambridge MA
Ex-Chiron · University of Paris VI PhD
Ex-Pfizer
Kings College in London
Rice University BS 2005, University of Utah PhD 2013 & MD 2016
Ex-Stirling Square Capital Partners, EMcision, Deutsche Bank. University of Bristol BSc 2007, Columbia Business School MBA 2013
CEO - cellcentric. London Business School Master of Business Administration 2001
Ex-MannKind, Medtronic, GE Healthcare, GE Appliances. Indiana University Bloomington MBA 2004, MS 2005
Ex-Vyome Therapeutics, Aratana Therapeutics, Ikaria · Kalamazoo College BA 1988, The University of Chicago Booth School of Business MBA 1992
Ex-Co-Founder Aiolos Bio, Gyroscope Therapeutics. Wolverhampton University, Aston University MBA
522 profiles with education records.
24 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
125,175 articles in the measured 12-month window.
Life Sciences coverage across United Kingdom · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 30,823 |
| 2021Q3 | 26,833 |
| 2021Q4 | 25,929 |
| 2022Q1 | 28,844 |
| 2022Q2 | 27,412 |
| 2022Q3 | 27,391 |
| 2022Q4 | 28,560 |
| 2023Q1 | 29,256 |
| 2023Q2 | 32,808 |
| 2023Q3 | 30,539 |
| 2023Q4 | 28,215 |
| 2024Q1 | 30,962 |
| 2024Q2 | 29,749 |
| 2024Q3 | 29,363 |
| 2024Q4 | 28,204 |
| 2025Q1 | 55,105 |
| 2025Q2 | 29,493 |
| 2025Q3 | 33,664 |
| 2025Q4 | 28,115 |
| 2026Q1 | 33,126 |
Article volume measures coverage, not market sales.
2,071 recorded company events across 322 companies; percentages use that event total.
Life Sciences coverage across United Kingdom · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across United Kingdom
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 1,032 | 437 | 136% |
| angel investors | 1,019 | 406 | 151% |
| free trade deals | 586 | 217 | 170% |
| vaccine candidates | 555 | 358 | 55% |
| bilateral trade | 518 | 124 | 318% |
| vaccine immunogenicity | 433 | 243 | 78% |
| trade dispute mechanisms | 421 | 154 | 173% |
| vaccination campaigns | 416 | 140 | 197% |
| asset acquisition | 413 | 141 | 193% |
| early-stage investment | 409 | 137 | 199% |
| investigational new vaccine | 125 | 461 | -73% |
| vaccine formulation | 161 | 421 | -62% |
| viral vector vaccines | 134 | 412 | -67% |
| diagnostic biotechnology | 169 | 349 | -52% |
| vaccine preclinical testing | 92 | 345 | -73% |
Life Sciences coverage across United Kingdom
inflation outlook, core inflation rate, inflation breakdown
54.0% critical · 32.2% positiveangel investors, early-stage investment, asset acquisition
45.5% critical · 50.6% positivegdp acceleration, gdp growth rate, inflation outlook
38.3% critical · 42.9% positiveLife Sciences coverage across United Kingdom. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.4 |
| 2023 | 59.2 |
| 2024 | 62.0 |
| 2025 | 66.9 |
Common problems researchers identify · 0216.8% of this theme group
Issues surrounding microbial hazards, nutritional quality, and health impacts of processed foods.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 69.7 |
| 2023 | 71.2 |
| 2024 | 76.2 |
| 2025 | 98.4 |
Common problems researchers identify · 0315.8% of this theme group
Barriers in controlling gene activity, mRNA delivery, and cell‑culture models for disease research.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2508.3 |
| 2023 | 2505.5 |
| 2024 | 2206.6 |
| 2025 | 1725.8 |
Common problems researchers identify · 0415.4% of this theme group
Limitations in fertilizer use, nutrient uptake, and breeding for resilient, high‑yield crops.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1631.9 |
| 2023 | 1660.6 |
| 2024 | 1795.2 |
| 2025 | 2000.4 |
Common problems researchers identify · 0515.3% of this theme group
Complexities of fungicide resistance, host‑pathogen interactions, and integrated pest strategies.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.7 |
| 2023 | 29.4 |
| 2024 | 27.9 |
| 2025 | 37.4 |
Common problems researchers identify · 069.9% of this theme group
Rising drug‑resistant bacteria in humans, livestock, and the environment.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 882.3 |
| 2023 | 835.4 |
| 2024 | 912.9 |
| 2025 | 968.7 |
Common problems researchers identify · 079.4% of this theme group
Broad, unrelated research areas lacking a clear thematic focus.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.2 |
| 2023 | 21.4 |
| 2024 | 17.1 |
| 2025 | 12.4 |
Cautions · 0121.5% of this theme group
Need for careful interpretation of in‑vitro and in‑vivo assays measuring stress responses.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1032.2 |
| 2023 | 1112.2 |
| 2024 | 911.3 |
| 2025 | 828.7 |
Cautions · 0214.6% of this theme group
Caution about translating theoretical genomic tools into practical crop improvement.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1433.4 |
| 2023 | 1471.3 |
| 2024 | 1631.9 |
| 2025 | 1793.7 |
Cautions · 0313.9% of this theme group
Potential unintended effects of bioactive feed compounds on animal health and sustainability.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 21.2 |
| 2023 | 19.9 |
| 2024 | 17.3 |
| 2025 | 17.6 |
Cautions · 0413.6% of this theme group
Uncertainties surrounding novel food ingredients, additives, and their safety assessments.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 92.1 |
| 2023 | 89.1 |
| 2024 | 94.2 |
| 2025 | 105.4 |
Cautions · 0513.5% of this theme group
Complexities in interpreting gene‑expression changes linked to genomic instability.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2414.1 |
| 2023 | 2426.1 |
| 2024 | 2133.7 |
| 2025 | 1642.1 |
Cautions · 0611.7% of this theme group
Risks of simultaneous resistance development to antibiotics, biocides, and metals.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 882.3 |
| 2023 | 835.4 |
| 2024 | 912.9 |
| 2025 | 968.7 |
Cautions · 0711.3% of this theme group
Challenges in designing dose strategies to mitigate evolving pesticide resistance.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.0 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 76.7 |
Opportunities · 0117.4% of this theme group
Emerging platforms for in‑vivo fluorescence, flow cytometry, and targeted immunotherapies.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 560.8 |
| 2023 | 617.6 |
| 2024 | 466.3 |
| 2025 | 459.8 |
Opportunities · 0217.2% of this theme group
Promising approaches using knockdown, apoptosis control, and cell‑growth modulation.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 362.8 |
| 2023 | 394.7 |
| 2024 | 255.9 |
| 2025 | 266.9 |
Opportunities · 0314.6% of this theme group
Development of antioxidant‑rich ingredients and health‑promoting dietary products.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 25.8 |
| 2024 | 27.4 |
| 2025 | 44.8 |
Opportunities · 0413.7% of this theme group
Innovations in DNA methylation profiling and miRNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2396.5 |
| 2023 | 2385.8 |
| 2024 | 2123.6 |
| 2025 | 1641.4 |
Opportunities · 0513.5% of this theme group
Exploration of plant‑derived compounds and postbiotic products to combat resistance.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.2 |
| 2024 | 556.9 |
| 2025 | 654.9 |
Opportunities · 0611.9% of this theme group
Leveraging quantitative trait loci and selection to boost crop yields and traits.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 52.7 |
| 2023 | 45.3 |
| 2024 | 39.3 |
| 2025 | 41.1 |
Opportunities · 0711.6% of this theme group
Utilizing microbial fermentation and agri‑food by‑products for greener energy and materials.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1511.1 |
| 2023 | 1558.6 |
| 2024 | 1735.8 |
| 2025 | 1952.4 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.8% |
| Promising | 30.4% | 37.0% |
| Breakthrough | 14.1% | 26.1% |
| Problem-identifying | 8.3% | 10.0% |
| Cautionary | 3.5% | 4.3% |
| Comparative | 2.4% | 3.9% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Compare demand signals in the United Kingdom’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Maternal & child health ↗Disease Burden | 71.4 | 33.3 | +38.1 | +33.0% | |
| Ageing & elder care ↗Disease Burden | 28.6 | 0.0 | +28.6 | +4.8% | |
| Layoffs & income shocks ↗Spending Pressure | 92.9 | 66.7 | +26.2 | +37.0% | |
| Infectious outbreaks ↗Disease Burden | 28.6 | 16.7 | +11.9 | +13.7% | |
| Air pollution ↗Environmental Driver | 14.3 | 50.0 | -35.7 | +6.7% | |
| Cancer burden ↗Disease Burden | 42.9 | 83.3 | -40.4 | -9.3% | |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 42.9 | 100.0 | -57.1 | +30.8% | |
| Mental health ↗Disease Burden | 78.6 | — | No matching category | — | +41.2% |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. the United Kingdom is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Infectious outbreaks · Cancer burden
Maternal & child health · Mental health · Cancer burden
Maternal & child health · Layoffs & income shocks · Cancer burden
Cancer burden · Maternal & child health · Layoffs & income shocks
Mental health · Layoffs & income shocks · Ageing & elder care
Maternal & child health · Cancer burden · Layoffs & income shocks
Cancer burden · Layoffs & income shocks · Maternal & child health
Cancer burden · Layoffs & income shocks · Mental health
Cancer burden · Ageing & elder care · Diabetes, hypertension & cardiac burden
Air pollution · Mental health · Maternal & child health
Layoffs & income shocks · Mental health · Maternal & child health
Maternal & child health · Layoffs & income shocks · Diabetes, hypertension & cardiac burden
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 254 | 11.47 |
| 2024Q4 | 288 | 13.29 |
| 2025Q1 | 242 | 9.57 |
| 2025Q2 | 210 | 10.39 |
| 2025Q3 | 533 | 22.02 |
| 2025Q4 | 169 | 9.72 |
| 2026Q1 | 215 | 10.84 |
| 2026Q2 | 125 | 13.95 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 128 | 5.78 |
| 2024Q4 | 219 | 10.11 |
| 2025Q1 | 215 | 8.5 |
| 2025Q2 | 186 | 9.2 |
| 2025Q3 | 276 | 11.4 |
| 2025Q4 | 97 | 5.58 |
| 2026Q1 | 163 | 8.22 |
| 2026Q2 | 82 | 9.15 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 414 | 18.7 |
| 2024Q4 | 385 | 17.77 |
| 2025Q1 | 570 | 22.55 |
| 2025Q2 | 428 | 21.18 |
| 2025Q3 | 663 | 27.39 |
| 2025Q4 | 400 | 23.01 |
| 2026Q1 | 634 | 31.96 |
| 2026Q2 | 243 | 27.12 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 74 | 3.34 |
| 2024Q4 | 133 | 6.14 |
| 2025Q1 | 145 | 5.74 |
| 2025Q2 | 120 | 5.94 |
| 2025Q3 | 176 | 7.27 |
| 2025Q4 | 90 | 5.18 |
| 2026Q1 | 114 | 5.75 |
| 2026Q2 | 43 | 4.8 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 117 | 5.28 |
| 2024Q4 | 115 | 5.31 |
| 2025Q1 | 119 | 4.71 |
| 2025Q2 | 134 | 6.63 |
| 2025Q3 | 188 | 7.77 |
| 2025Q4 | 82 | 4.72 |
| 2026Q1 | 87 | 4.39 |
| 2026Q2 | 51 | 5.69 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 321 | 14.5 |
| 2024Q4 | 407 | 18.78 |
| 2025Q1 | 533 | 21.08 |
| 2025Q2 | 414 | 20.48 |
| 2025Q3 | 420 | 17.35 |
| 2025Q4 | 307 | 17.66 |
| 2026Q1 | 316 | 15.93 |
| 2026Q2 | 154 | 17.19 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 112 | 5.06 |
| 2024Q4 | 106 | 4.89 |
| 2025Q1 | 133 | 5.26 |
| 2025Q2 | 170 | 8.41 |
| 2025Q3 | 182 | 7.52 |
| 2025Q4 | 158 | 9.09 |
| 2026Q1 | 137 | 6.91 |
| 2026Q2 | 60 | 6.7 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 161 | 7.27 |
| 2024Q4 | 222 | 10.25 |
| 2025Q1 | 200 | 7.91 |
| 2025Q2 | 204 | 10.09 |
| 2025Q3 | 362 | 14.95 |
| 2025Q4 | 193 | 11.1 |
| 2026Q1 | 222 | 11.19 |
| 2026Q2 | 99 | 11.05 |
the United Kingdom life sciences coverage
BMJ
1,387 citations in the snapshot
The Lancet
1,270 citations in the snapshot
1,226 citations in the snapshot
BMJ
692 citations in the snapshot
the United Kingdom coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| vaccine misinformation impact | 105 | 23 | 479.2% |
| continuing education immunization | 121 | 27 | 468.6% |
| vaccination-induced herd protection | 86 | 22 | 396.0% |
| pediatric catch-up vaccinations | 189 | 62 | 286.8% |
| exercise oncology | 67 | 47 | 80.9% |
| blood pressure reduction rate | 41 | 30 | 73.4% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
52.2% across the displayed hubs
39 companies hiring · $12.7B disclosed funding
Explore companies in London ↗
18.9% across the displayed hubs
23 companies hiring · $8.3B disclosed funding
Explore companies in Cambridge ↗
10.4% across the displayed hubs
8 companies hiring · $4.6B disclosed funding
Explore companies in Oxford ↗
5.2% across the displayed hubs
3 companies hiring · $978.7M disclosed funding
Explore companies in Edinburgh ↗
4.5% across the displayed hubs
4 companies hiring · $758.8M disclosed funding
Explore companies in Manchester ↗
3.0% across the displayed hubs
3 companies hiring · $314.0M disclosed funding
Explore companies in Glasgow ↗
3.0% across the displayed hubs
4 companies hiring · $57.1M disclosed funding
Explore companies in Sheffield ↗
2.8% across the displayed hubs
2 companies hiring · $316.3M disclosed funding
Explore companies in Cardiff ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 6 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗